Compare Cincinnati Financial Corporation (CINF) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cincinnati Financial Corporation vs Regeneron Pharmaceuticals Inc — how do they compare? Cincinnati Financial Corporation trades at $173.45 (market cap $26.68B), while Regeneron Pharmaceuticals Inc trades at $796.32 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 3.1× Cincinnati Financial Corporation's market cap, and Cincinnati Financial Corporation pays the higher dividend (2.16%). Which is the better fit depends on your goals.
| CINF | REGN | |
|---|---|---|
Market Cap | $26.68B | $83.19B |
Sector | Financials | Health |
52-Week High | $192.03 | $812.27 |
52-Week Low | $149.79 | $545.94 |
Enterprise Value | $25.80B | $77.90B |
Dividend Yield | 2.16% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cincinnati Financial (CINF) trades at $176.86, down 1.22% on the day, with a bearish technical signal but strong fundamentals including a P/E of 8.35 and ROE of 21.48%. Recent Q2 2026 earnings missed estimates at $1.43 per share versus $1.84 expected, though revenue grew year-over-year. The company maintains robust cash flow, with 2025 operating cash flow at $3.11 billion, and a consistent dividend history, including a recent $0.94 payout.
Outlook is mixed: valuation appears attractive with analyst consensus price target of $195, but near-term headwinds include catastrophe losses and commercial lines weakness. Long-term growth is supported by premium expansion and investment income, though investors face risks from underwriting volatility and economic sensitivity.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cincinnati Financial Corporation
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.
Read more on CINF →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
